Open AccessTreatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)
Author(s) -
Khalifa E. Sharquie,
Adil A. Noaimi,
Ahmed G. Al-Ghazzi
Publication year - 2015
Publication title -
journal of dermatology and dermatologic surgery
Language(s) - English
Resource type - Journals
eISSN - 2352-2429
pISSN - 2352-2410
DOI - 10.1016/j.jdds.2014.10.001
Subject(s) - medicine , podophyllin , cutaneous leishmaniasis , lesion , dermatology , surgery , leishmaniasis , target lesion , pathology , percutaneous coronary intervention , myocardial infarction
AbstractBackgroundThere are many therapies that had been used to treat cutaneous leishmaniasis (CL).ObjectiveTo evaluate the effectiveness of topical 25% podophyllin solution in treatment of CL.Patients and methodsSixty-five patients with acute CL enrolled in this study, which was done in the Department of Dermatology, Baghdad Teaching Hospital, Baghdad, during January 2008–April 2009.The total number of lesions was 124 and duration of lesions ranged from 3 to 12(6.84±2.902)weeks. The size of lesions ranged from 0.5 to 3(1.75±1.81)cm. Diagnosis was confirmed by biopsy and smear. Lesions were divided into two groups with matching of type and size of lesionsGroup A treated with topical 25% podophyllin solution once weekly for number of sessions ranged from 3 to 6(4.51±0.85) sessions.Group B was left untreated as a control group. Follow up was every 2weeks for 8weeks.ResultsThe total number of lesions was 120:79(65.84%) were ulcerated and 41(34.16%) were dry and 25(40.32%) patients had single lesion while 37(59.677%) patients had multiple lesions.Group A: 51(85%) lesions out of 60 lesions had cure with number of sessions ranging from 3 to 6(5.137±0.9385) sessions.Group B: no lesion was cured.ConclusionsTopical 25% podophyllin is a new effective topical therapy for CL, with few side effects